BACKGROUND: Ovarian clear cell adenocarcinoma is associated with one of the poorest prognoses among human epithelial ovarian cancers. The authors hypothesized that Wilms tumor suppressor 1 gene (WT1) sense and antisense (WT1-AS) expression and their promoter methylation status could characterize ovarian clear cell adenocarcinoma from ovarian serous adenocarcinoma. METHODS: To test this hypothesis, ovarian cancer cell lines and 42 cancer tissues (17 clear cell and 25 serous adenocarcinoma) were analyzed for expression and methylation of WT1 and WT1-AS genes. RESULTS: These experiments demonstrated that all serous adenocarcinoma tissues expressed both WT1 and WT1-AS genes, although expression of these genes was lacking in clear cell adenocarcinoma. The WT1 and WT1-AS promoter were significantly methylated in clear cell adenocarcinoma (88.2% and 88.2%, respectively) compared with serous adenocarcinoma (24.0% and 20.0%, respectively). Significant correlation between methylation and mRNA expression status was observed for each gene. Also in agreement with these data, WT1 and WT1-AS negative ovarian cancer cell lines reexpressed these genes after treatment with the demethylating agent, 5-aza-2'-deoxycytidine. CONCLUSIONS: The current study shows that CpG hypermethylation is an important mechanism of WT1 and WT1-AS gene inactivation in ovarian clear cell adenocarcinoma. This is the first report that has demonstrated differential expression and methylation of WT1-AS in ovarian clear cell and serous adenocarcinomas. This study presents new molecular characterizations between these two types of adenocarcinoma and may provide insight as to why clear cell adenocarcinoma has a poorer prognosis than serous adenocarcinoma of the ovary. (c) 2005 American Cancer Society.
BACKGROUND:Ovarian clear cell adenocarcinoma is associated with one of the poorest prognoses among humanepithelial ovarian cancers. The authors hypothesized that Wilms tumor suppressor 1 gene (WT1) sense and antisense (WT1-AS) expression and their promoter methylation status could characterize ovarian clear cell adenocarcinoma from ovarian serous adenocarcinoma. METHODS: To test this hypothesis, ovarian cancer cell lines and 42 cancer tissues (17 clear cell and 25 serous adenocarcinoma) were analyzed for expression and methylation of WT1 and WT1-AS genes. RESULTS: These experiments demonstrated that all serous adenocarcinoma tissues expressed both WT1 and WT1-AS genes, although expression of these genes was lacking in clear cell adenocarcinoma. The WT1 and WT1-AS promoter were significantly methylated in clear cell adenocarcinoma (88.2% and 88.2%, respectively) compared with serous adenocarcinoma (24.0% and 20.0%, respectively). Significant correlation between methylation and mRNA expression status was observed for each gene. Also in agreement with these data, WT1 and WT1-AS negative ovarian cancer cell lines reexpressed these genes after treatment with the demethylating agent, 5-aza-2'-deoxycytidine. CONCLUSIONS: The current study shows that CpG hypermethylation is an important mechanism of WT1 and WT1-AS gene inactivation in ovarian clear cell adenocarcinoma. This is the first report that has demonstrated differential expression and methylation of WT1-AS in ovarian clear cell and serous adenocarcinomas. This study presents new molecular characterizations between these two types of adenocarcinoma and may provide insight as to why clear cell adenocarcinoma has a poorer prognosis than serous adenocarcinoma of the ovary. (c) 2005 American Cancer Society.
Authors: Ken Yamaguchi; Zhiqing Huang; Noriomi Matsumura; Masaki Mandai; Takako Okamoto; Tsukasa Baba; Ikuo Konishi; Andrew Berchuck; Susan K Murphy Journal: Int J Cancer Date: 2014-01-14 Impact factor: 7.396
Authors: Ying Qu; Andreas Lennartsson; Verena I Gaidzik; Stefan Deneberg; Mohsen Karimi; Sofia Bengtzén; Martin Höglund; Lars Bullinger; Konstanze Döhner; Sören Lehmann Journal: Epigenetics Date: 2014-05-27 Impact factor: 4.528
Authors: J N Jeyapalan; D A Mohamed Noor; S-H Lee; C L Tan; V A Appleby; J P Kilday; R D Palmer; E C Schwalbe; S C Clifford; D A Walker; M J Murray; N Coleman; J C Nicholson; P J Scotting Journal: Br J Cancer Date: 2011-06-28 Impact factor: 7.640
Authors: Anthony R Dallosso; Anne L Hancock; Sally Malik; Ashreena Salpekar; Linda King-Underwood; Kathy Pritchard-Jones; Jo Peters; Kim Moorwood; Andrew Ward; Karim T A Malik; Keith W Brown Journal: RNA Date: 2007-10-16 Impact factor: 4.942
Authors: Lee F Starker; Jessica Svedlund; Robert Udelsman; Henning Dralle; Göran Akerström; Gunnar Westin; Richard P Lifton; Peyman Björklund; Tobias Carling Journal: Genes Chromosomes Cancer Date: 2011-06-02 Impact factor: 5.006
Authors: A G Schache; G Hall; J A Woolgar; G Nikolaidis; A Triantafyllou; D Lowe; J M Risk; R J Shaw; T Liloglou Journal: Br J Cancer Date: 2010-11-09 Impact factor: 7.640